Intrathecal non-viral interleukin-10 gene therapy ameliorates neuropathic pain as measured by both classical static allodynia and a novel supra-spinally mediated pain assay, the Two-Arm Rodent Somatosensory (TARS) task

• Published in: Brain, behavior, and immunity behavior, and immunity, 2023-07, Vol.111, p.177-185
• Main Authors: Clements, M.A., Kwilasz, A.J., Litwiler, S.T., Sents, Z., Woodall, B.J., Hayashida, K., Watkins, L.R.
• Format: Article
• Language: English
• Subjects: Allodynia; Chronic constriction injury; DNA; Genetic Therapy; Humans; Hyperalgesia - drug therapy; Interleukin-10 - metabolism; Maze learning; Neuralgia - metabolism; Operant task; Rats
• ISSN: 0889-1591; 1090-2139; 1090-2139
• DOI: 10.1016/j.bbi.2023.04.002

•Intrathecal (IT) pDNA IL-10 reverses spinally-mediated measures of neuropathic pain.•Development of TARS, a new 2-arm choice task to assess supraspinal pain processing.•Spinal and supraspinal indices of neuropathic pain developed in parallel over time.•Both indices of pain were reversed in parallel after IT pDNA-IL10 gene therapy.•Details for construction and use of the TARS operant behavior task are provided. Intrathecal delivery of interleukin-10 (IL-10) gene therapy has been reported to be effective in suppressing pain enhancement in a variety of rodent models. However, all publications that have tested this treatment have relied upon measures of static allodynia (von Frey test) and thermal hyperalgesia (Hargreaves test). As this plasmid DNA IL-10 (pDNA-IL10) therapeutic approach is now in human clinical trials for multiple pain indications, including intrathecal delivery for human neuropathic pain, it is important to consider the recent concerns raised in the pain field that such tests reflect spinal rather than supraspinal processing of, and responsivity to, noxious stimuli. Consequently, this raises the question of whether intrathecal pDNA-IL10 can reverse established neuropathic pain when assessed by a test requiring supraspinal, rather than solely spinal, mediation of the behavioral response. The present study utilizes the rat sciatic chronic constriction injury (CCI) model of neuropathic pain to compare the expression of static allodynia with that of cognitively controlled choice behavior in a two-arm maze, adapted from Hayashida et al. (2019). This modification, termed the Two-Arm Rodent Somatosensory (TARS) task, provides rats free choice to reach a desired goal box via a short “arm” of the maze with tactile probes as flooring versus a longer “arm” of the maze with a smooth surface. Here we demonstrate that static allodynia and avoidance of the nociceptive flooring in TARS develop in parallel over time, and that both behaviors also resolve in parallel following intrathecal pDNA-IL10 gene therapy. Details for the construction and use of this new maze design are also provided. Together, this study documents both: (a) the important finding that intrathecal IL-10 gene therapy does indeed resolve neuropathic pain as measured by a supraspinally-mediated behavioral task, and (b) a new, supraspinally-mediated task that allows behavioral assessments across weeks and allows the analysis of both development and resolution of neuropathic pain by therapeuti